Baird served as a co-manager on this offering
AboutCerus Corporation (“Cerus” or the “Company”) (NASDAQ: CERS) recently completed a follow-on offering of 9,583,333 shares of common stock at a price of $4.20 per share, generating gross proceeds of approximately $40.2 million. The net proceeds from the offering will be used for clinical development and other research and development activities related to the INTERCEPT Blood System, preparatory activities for the potential commercialization of the INTERCEPT Blood System in the United States and elsewhere as well as for general corporate purposes.
Cerus is a biomedical products company focused on enhancing blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe and other selected countries around the world. In the United States, Cerus is seeking regulatory approval of the INTERCEPT Blood System for plasma, and is in the process of determining the application shell for a potential regulatory submission for the INTERCEPT Blood System for platelets. The INTERCEPT red blood cell system is in clinical development. Cerus is headquartered in Concord, California.
For additional information about this transaction, please contact:
- March 2013
- Cerus Corporation
- Target Location
- North America